First-in-class nanowire-based molecular cancer diagnostics
Unlocking better patient care by using precision medicine to accelerate clinical decision-making.
About Genopsy
Genopsy is a preclinical-phase diagnostics company developing a platform to detect lung cancer–associated molecular signatures with high sensitivity and near-real-time clinical decision support.
Our novel diagnostic platform integrates:
- First-in-class, nanowire-based biosensing architecture (not PCR-based)
- Multi-analyte detection from a single blood sample
- Rapid analytical processing with a 2-hour turnaround
Unlike conventional, sequencing-based or single-analyte assays, Genopsy’s platform is designed to detect lung cancer–associated molecular signatures with high analytical sensitivity, while enabling near-real-time clinical decision support and longitudinal monitoring.
Genopsy has established its U.S. regulatory and commercialization presence in New Jersey, a major global hub for life sciences, biotechnology and the pharmaceutical industry.
Analytical and clinical validation in NSCLC is expected to start in early 2027.
An urgently-needed revolution
Current lung cancer diagnostics are limited.
Bronchoscopies and biopsies are invasive, risky procedures with technical limitations. Biopsy tissue can be limited, and poor-quality samples are common. 15% of screens may miss cancer. NGS testing is complex, expensive and slow, delaying decision-making. Treatment efficacy may be challenging to understand. Relapse may be hard to recognize. As cancer progresses, resistance mutations develop.
At every step, the cost of inaction is high.
With about 2.5 million new cases in 2025, the problem is enormous: Lung cancer is the leading cause of cancer around the world, and the leading cause of cancer deaths. In 2025, that meant:
New US cases
New EU cases
New cases in Asia
Most lung cancer patients are diagnosed at a late stage, with poor prognosis. About 77% of those diagnoses are NSCLC.
There is a clear, urgent unmet need for a rapid, patient-friendly (minimally invasive) diagnostic that accelerates accurate decision-making, saving lives and money. Our first-in-class platform is that diagnostic revolution.
We are enabling a new diagnostic paradigm for NSCLC, with comprehensive genomic profiling, same-day decision impact, and strong reimbursement leverage.
Our technology
A simplified, faster workflow helps more patients get treatment sooner.
Genopsy's easy-to-operate, benchtop-sized, multi-analyte liquid biopsy platform features a 2-hour turnaround from blood draw to report.
It's that simple. Here's how:
1. Liquid sample collection
Standard blood draw (no imaging or biopsy).
2. Capture & detection
Nanowires bind circulating tumor DNA (ctDNA). Tumor-specific probes bind to biomarker locations, and produce measurable, colorimetric signals.
3. Automated analysis
Integrated interpretation of biomarker patterns. Can be used with mutations, insertions or deletions (indels), gene fusion, etc.
4. Actionable diagnostic report
Clear results with a personalized, comprehensive molecular profile, enabling earlier decision-making that helps patients.
The foundations of Genopsy technology
A simplified and faster workflow (PCR-free detection)
Unlike most conventional approaches (ddPCR, standard NGS) that rely on PCR to amplify trace amounts of ctDNA, Genopsy’s conductive polymer nanowire biosensor directly detects DNA variants and mutations. Our integrated platform uses HRP enzyme signal amplification and a colorimetric readout - no complex and time-consuming DNA amplification steps, minimizing amplification-related errors and bias that commonly affect the detection of extremely low-frequency ctDNA mutations.
This also enables a much faster turnaround time, with some results available in as little as one hour, compared to 20–39 days for comprehensive genomic profiling.
Ultra-high sensitivity for rare mutations
The physical properties of our nanowire technology enables highly efficient capture and sensing of target DNA. This allows us to capture short ctDNA fragments (~167bp), with up to 80% efficiency for fragments as small as 100bp – a critical advantage since ctDNA is typically shorter than non-tumor cfDNA.
Genopsy’s unique, thread-like nanowire structures increase contact with rare, tumor-specific biomarkers that circulate in blood, increasing capture yield. More captured DNA helps us better detect mutations.
Multi-omics detection
We detect more than point mutations. Our platform leverages locally denatured regions of fragmented ctDNA, as well as transiently open DNA structures that naturally arise during transcription and other regulatory processes. These partially accessible regions expose nucleotide sequences and conformational signatures that reflect not only DNA mutations, but also higher-order regulatory or expression-associated events.
By targeting these open and accessible structures, our nanowire system can detect signals associated with fusion genes and protein overexpression at the DNA level, even though such biomarkers are typically measured using RNA- or protein-based assays.
This enables our first-in-class platform to deliver a truly integrated, multi-omic readout within a single assay, eliminating the need for separate workflows for DNA, RNA and protein analysis. We can detect an 8-target panel: six EGFR variants, EML4-ALK fusion, KRAS G12C, and more.
We're just getting started. Our category-defining platform also has extensibility beyond lung cancer. Contact us to learn more.
A revolutionary approach
The Genopsy platform delivers a precise, cost-efficient and rapid liquid biopsy solution that simplifies clinical workflows and significantly improves sensitivity for detecting minimal residual disease (MRD) by eliminating the need for complex molecular steps.
Learn more about how we are changing the landscape of lung cancer diagnosis.
Robust IP Portfolio
No FDA-cleared or approved conductive polymer nanowire in-vitro diagnostic device (IVD) exists.
Genopsy Inc. holds a 31-patent portfolio for this transformative suite of technology.
Clinical advantages
We’re improving patient care by making diagnoses faster, more accessible and more cost-effective, unlocking earlier treatment that can save and extend lives.
Patient friendly
Minimally invasive blood draw without CT, bronchoscopy, or invasive biopsy, reducing patient risk and improving patient comfort.
Early disease detection
Sensitivity optimized for low tumor burden, complementing imaging. Use with high-risk patients under surveillance and patients with indeterminate nodules.
Tests multiple targets
Multiplexing automatically detects a panel of ctDNA biomarkers, with extensibility to RNA and proteins.
Rapid results
Quick turnaround - 2 hours to results - enables real-time therapy decisions, using less tissue.
No need to “wait and see.” Our first-in-class platform enables decentralized, point-of-care testing in virtually any healthcare setting. We are enabling a new lung cancer diagnostic category with same-day clinical decision-making and strong reimbursement leverage.
High risk populations and patients with indeterminate nodules can get more frequent, minimally invasive, cost-effective assessments. Longitudinal monitoring becomes feasible. Clinicians can get molecular confirmation prior to ordering invasive biopsy procedures.
By complementing imaging and supporting earlier detection, we offer precision medicine insights in nearly every clinical setting. And with platform extensibility beyond lung, the revolution is just beginning.
Healthcare system advantages
We’re reducing the time, cost and complexity of lung cancer diagnosis, helping providers and healthcare systems deliver better, more efficient care, with strong reimbursement leverage.
Easy integration into any clinical setting
Designed for ease of use even in low-resource community clinics, not just large hospitals. Compatible with existing lab workflows, without requiring Next-Generation Sequencing (NGS)-scale infrastructure or specialty operators.
80-95% reduction in time to treatment
Reduced from 14–28 days under current NGS workflows to approximately 1–3 days. Treating patients earlier is better for the pathology of cancer, and better for the mental health of patients.
40-45% reduction in Next-Generation Sequencing (NGS)
Avoiding NGS lowers costs and laboratory burden. Unlike current practice where nearly all patients undergo NGS, we enable NGS to be used only when it’s needed, helping providers and health systems.
80% reduction in required tissue
Across the treatment journey, Genopsy enables a decrease from 5–10 slides and 200–400ng of DNA to only 1–2 slides and 50–100ng of DNA, reducing complexity and the strain on histopathology labs.
Genopsy history
A track record of achievement. Positioned for success.
2017 - 2018
Discovery of core technologies and company founding
Following the discovery of the DNA bubble as a new biomarker, Genopsy Co., Ltd. was established as the first spin-off company from the Korean National Cancer Center.
2018 - 2020
Research and technology exploration
Genopsy received technology transfer, and was subsequently certified as a Venture Company by the Korea Technology Finance Corporation (KIBO).
Raised $9.3M USD in Series A investment. Research continued into controlling DNA bubble size, and identifying sample and reagent conditions, and experimental methods.
2020 - 2024
Research on analytical processes for commercialization
Intellectual property was registered in key countries. Genopsy established a research institute and advanced DNA bubble-based, non-PCR analytical processes. Development focused on experimental equipment, consumables, and test bed/engineering samples.
2025
Prototype design, research, and development
Development of the Genesys Analysis Platform continued, with prototype performance testing and evaluation, development of prototype reagent kits and the preparation and compilation of technical documentation.
Genopsy US was established in November, 2025.
Leadership
Experts in the field of nanowire DNA technology, liquid biopsy, lung cancer, biotechnology, translational research and regulatory affairs.
Youngnam Cho, Ph.D.
Founder & CEO Genopsy Bio
Principal Investigator, National Cancer Center Graduate School (Korea). Research expertise includes circulating tumor DNA (ctDNA) and nanoscale biosensors for early disease detection.
Dan Kim
CEO Genopsy - US
Senior pharma management and commercialization leader (Roche, Wyeth, Novartis), including the launch of billion-dollar products in US and global markets.
David Lim, Ph.D.
US Regulatory
More than two decades of FDA-focused experience, translating scientific innovation into globally compliant, market-ready diagnostics.
Robert Poorvin
VP of Clinical Technologies
Senior IT executive with extensive experience in creating new services & products that transform corporations using internal & outsourced resources.
Emmanuel Zachariah, PhD
Technical Director
Accomplished scientist and biotechnology executive with over 25 years of experience in cancer genomics, molecular diagnostics, precision oncology, and translational research. Scientific Director at Rutgers Cancer Institute and Founder and CEO of OncoPath Genomics.
David Kalb
Independent Board Member
Over 40 years of experience developing educational and training programs for patients, physicians, pharmacists, and healthcare sales professionals. Founding member and Managing Partner of Diversified Medical Communications, Inc.
Matt Feldman
Communications Advisor
Scientist turned communicator and innovative storytelling leader, with more than 15 years making complex information accessible. Global R&D Communications, Corporate Affairs, and patient engagement expertise.
Get in touch